NY-703

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameNY-703
Drug Alias NameNY-703
ClassificationRadiation-emitting products > Nuclides > Astatine > 211AtBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics
Mechanisms of ActionAnti-Glypican-3
TargetsGlypican-3
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNAYA Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNAYA Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A